Bupropion as a modulator of drug activity
AssigneeAntecip Bioventures II LLC
InventorHerriot Tabuteau
Life of this patent
Estimating the term…
Abstract
This disclosure relates to methods administering bupropion or a prodrug thereof in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion or a prodrug of bupropion are also disclosed.
Claims12
A method of increasing dextromethorphan plasma levels in a human being, comprising co-administering about 150 mg per day to about 500 mg per day of bupropion with dextromethorphan to the human being for at least eight consecutive days, wherein bupropion and dextromethorphan are administered once or twice a day, wherein the human being is an extensive metabolizer of dextromethorphan in need of treatment with dextromethorphan, and wherein on the eighth day, the co-administration results in an AUC0-12 of dextromethorphan that is at least about 20 times the AUC0-12 that would be achieved by administering the same amount of dextromethorphan without bupropion for eight consecutive days.
A method of increasing dextromethorphan plasma levels in a human being, comprising co-administering about 150 mg per day to about 500 mg per day of bupropion with dextromethorphan to the human being for at least eight consecutive days, wherein bupropion and dextromethorphan are administered once or twice a day, wherein the human being is in need of treatment with increased plasma levels of dextromethorphan, and wherein on the eighth day, the co-administration results in a Cmax of dextromethorphan that is at least about 20 times the Cmax that would be achieved by administering the same amount of dextromethorphan without bupropion for eight consecutive days.
A method of increasing dextromethorphan plasma levels in a human being, comprising co-administering about 150 mg per day to about 500 mg per day of bupropion with dextromethorphan to the human being for at least eight consecutive days, wherein bupropion and dextromethorphan are administered once or twice a day, wherein the human being is in need of treatment with increased plasma levels of dextromethorphan, and wherein on the eighth day, the co-administration results in a Cavg of dextromethorphan over the period between two separate and consecutive administrations of dextromethorphan that is at least about 20 times the Cavg that would be achieved by administering the same amount of dextromethorphan without bupropion for eight consecutive days.
Dependencies are inferred from the claim text.